Mimedx Group, Inc. (MDXG) · Oct 16, 2026 · Acquisition

MiMedx acquisition gets FTC second request, delaying Sanara close

FTC second request — 30-day HSR waiting period after substantial compliance

MiMedx’s acquisition gets an FTC second request, extending antitrust review and making the planned Sanara closing less routine.

MiMedx is trying to expand from its advanced-wound-care base into a broader surgical regenerative-medicine platform through the planned Sanara acquisition, which management previously positioned as nearly doubling surgical revenue and adding more than $20 million in annualized cost synergies.

The deal has moved from routine approval into deeper antitrust scrutiny. MiMedx and Sanara each received an FTC “Second Request” for additional information on October 15, 2026. 〔0〕 That is a new procedural hurdle, not evidence that the transaction is blocked, but it makes the previously targeted year-end closing timeline less certain.

The immediate effect is delay, not a changed deal price or strategy. The request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, unless the parties voluntarily extend it or the FTC ends the review sooner. 〔1〕

The acquisition thesis remains intact, but execution risk is higher. The filing says closing still depends on HSR clearance and the other merger conditions, while MiMedx says it is continuing to work with the FTC. 〔2〕 The direction of regulatory review was already known; the surprise is that the FTC wants a much deeper information set before allowing the clock to run.

Bottom line: This is a modest setback to MiMedx’s surgical-expansion plan, adding time and regulatory uncertainty without yet undermining the Sanara transaction itself.

What to watch next

Substantial compliance with FTC request, then 30-day waiting period

Original filing on SEC EDGAR

More Mimedx Group, Inc. news

MiMedx acquisition gets FTC second request, delaying Sanara close | MDXG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.